49Z Stock Overview
Operates as a bioconvergence company in North America, Europe, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BICO Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr3.77 |
| 52 Week High | kr6.35 |
| 52 Week Low | kr2.05 |
| Beta | 2.33 |
| 1 Month Change | -0.58% |
| 3 Month Change | -12.23% |
| 1 Year Change | -27.04% |
| 3 Year Change | -90.81% |
| 5 Year Change | n/a |
| Change since IPO | -58.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 49Z | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -0.7% | -0.8% | -0.4% |
| 1Y | -27.0% | -12.0% | 4.2% |
Return vs Industry: 49Z underperformed the German Life Sciences industry which returned -12% over the past year.
Return vs Market: 49Z underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| 49Z volatility | |
|---|---|
| 49Z Average Weekly Movement | 13.6% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 49Z's share price has been volatile over the past 3 months.
Volatility Over Time: 49Z's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 880 | Maria Forss | www.bico.com |
BICO Group AB (publ) operates as a bioconvergence company in North America, Europe, Asia, and internationally. It operates through three segments: Bioprinting, Biosciences, and Bioautomation. The Bioprinting segment offers products, solutions, and services that enable proliferation of 3D cell culture and 3D printing.
BICO Group AB (publ) Fundamentals Summary
| 49Z fundamental statistics | |
|---|---|
| Market cap | €265.96m |
| Earnings (TTM) | -€141.64m |
| Revenue (TTM) | €208.38m |
1.3x
P/S Ratio-1.9x
P/E RatioIs 49Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 49Z income statement (TTM) | |
|---|---|
| Revenue | kr2.43b |
| Cost of Revenue | kr716.50m |
| Gross Profit | kr1.71b |
| Other Expenses | kr3.36b |
| Earnings | -kr1.65b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 20, 2024
| Earnings per share (EPS) | -23.37 |
| Gross Margin | 70.47% |
| Net Profit Margin | -67.97% |
| Debt/Equity Ratio | 47.1% |
How did 49Z perform over the long term?
See historical performance and comparison